Business
BioDlink and Lepu Biopharma Celebrate Successful Launch of the World's First EGFR-Targeting ADC Drug, Marking a Major Milestone in Mutual Collaboration in Biologics CMC
On November 20, 2025, BioDlink (Stock Code: 1875.HK), a leading biologics CDMO, together with Lepu Biopharma (2157.HK), announced the successful market launch of MEIYOUHENG®(Becotatug Vedotin injection) , the world's first EGFR-targeting antibody-drug conjugate (ADC). The launch also represents the first ADC fully manufactured by a CDMO to reach the market in China, underscoring a new level of maturity for the region's biopharmaceutical ecosystem.
About this update from Lepu Biopharma Co. Ltd. Class H
[{"type":"list","items":[{"val":[{"type":"text","content":"Celebrating a Shared Milestone: BioDlink and Lepu Biopharma celebrated the launch of MEIYOUHENG®, the world's first EGFR-Targeting ADC, and their partnership spanning over two years.","length":186,"tagName":"p"}]},{"val":[{"type":"text","content":"Demonstrating Robust Capabilities: Throughout the collaboration, all technology transfers and GMP manufacturing batches were achieved successfully in a single attempt, underscoring robust commercial capability and a top-tier quality system of BioDlink.","length":252,"tagName":"p"}]},{"val":[{"type":"text","content":"The first ADC fully manufactured by a CDMO to reach the market in China, underscoring a new level of maturity for the region's biopharmaceutical ecosystem.","length":164,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":602,"olType":false},{"type":"text","content":"SUZHOU, China, Nov. 21, 2025 /PRNewswire/ -- On November 20, 2025, BioDlink (Stock Code: 1875.HK), a leading biologics CDMO, together with Lepu Biopharma (2157.HK), announced the successful market launch of MEIYOUHENG®(Becotatug Vedotin injection) , the world's first EGFR-targeting antibody-drug conjugate (ADC). The launch also represents the first ADC fully manufactured by a CDMO to reach the market in China, underscoring a new level of maturity for the region's biopharmaceutical ecosystem.","length":509,"tagName":"p"},{"type":"image","alt":"logo (PRNewsfoto/BioDlink Biopharm Co., Ltd.)","displaySize":"","headline":null,"caption":"logo (PRNewsfoto/BioDlink Biopharm Co., Ltd.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":82,"url":"https://media.zenfs.com/en/prnewswire.com/40591ea8ba443c2f8ddacfe8dc9169da"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bfhnGYVbJOyrwWPdCvLAIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE0NTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/40591ea8ba443c2f8ddacfe8dc9169da","width":400,"height":82}},"href":"https://mma.prnewswire.com/media/2682341/BioDlink_EN_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Senior leadership and project teams from both companies gathered at BioDlink's Suzhou headquarters to commemorate this achievement—a milestone that reflects deep scientific collaboration, disciplined execution, and shared commitment to advanc...